Retatrutide price is almost always quoted per vial, which is the least useful of the three ways to measure it. Per milligram is the number that lets you compare two sellers, and cost per research unit is the number that tells you what a working phase of a protocol actually costs.
Key takeaways
- Two vial sizes set the market reference: 10 mg at $99.00 list, $49.50 with the code, and 30 mg at $250.00 list, $125.00 with the code.
- Per milligram that is $4.95 against $4.17. Buying 30 mg as three separate 10 mg vials costs $148.50 for the same quantity, so the larger vial saves $23.50 on identical material.
- There is no insurance angle. Retatrutide has no marketing authorization anywhere, so there is no approved product for a plan to cover and no cash-versus-copay comparison to run.
- Bulk tiers take 3% off list at three units, 5% at five, and 10% at ten, and free shipping starts above $250. Confirm at checkout which total those thresholds read.
- On a body-composition budget the vial is not the largest line. Protecting lean mass during a fast loss phase costs protein, training time, and measurement, and none of that is optional.
The vendor we point lifters to
Retatrutide from Ascension Peptides
Independently assayed material, dispatched from the US. Both vial sizes drop by half with the code below.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 18, 2026.
The retatrutide price table, three ways
Sticker price, discounted price, and unit price are three different questions. Here they are side by side.
| Vial | List price | With code PEPTIDEDECK | Cost per mg | Free shipping at this spend |
|---|---|---|---|---|
| R-10, 10 mg | $99.00 | $49.50 | $4.95 | No |
| R-30, 30 mg | $250.00 | $125.00 | $4.17 | Not on the discounted total alone |
| 3 x R-10, 30 mg total | $297.00 | $148.50 | $4.95 | Depends which total the threshold reads |
The last row is the one worth sitting with. Three 10 mg vials and one 30 mg vial contain the same quantity of material. The route you pick changes the bill by $23.50 and changes nothing about what you receive, other than the number of stoppers you have to keep sterile.
Retatrutide cost without insurance is the only retatrutide cost
Searches for retatrutide cost without insurance carry an assumption that does not hold here. Insurance covers approved products. Retatrutide is Eli Lilly's investigational triple agonist of the GIP, GLP-1 and glucagon receptors, currently in the Phase 3 TRIUMPH program, and it holds no authorization from the FDA or any comparable regulator.
That means there is no National Drug Code for a plan to reimburse, no pharmacy to bill, and no prior authorization to fight. Every dollar is cash, and the comparison shoppers reach for, cash price against copay, has nothing on the other side of it.
It is a genuinely different situation from the approved incretins. Tirzepatide and semaglutide do have coverage pathways, savings cards and cash-pay vial programs, and the arithmetic there is worth doing carefully. Our guides to GLP-1 medications and cheapest tirzepatide handle that market. This page does not, because there is no equivalent to handle.
Where the two vial tiers actually separate
The per-milligram gap between the sizes is $0.78, or about 16% cheaper on the 30 mg. That is the whole of the pricing argument, and it is smaller than the packaging makes it look.
What tips the decision is not usually the 16%. It is whether you have already satisfied yourself about the supplier. A 10 mg vial at $49.50 is an inexpensive way to see whether the lot number on the vial matches the lot number on the certificate you were shown, whether the cake arrived intact, and whether the invoice describes research material. Buying the cheaper unit price before running those checks means committing three times the money to an unverified answer.
Once the checks pass, the per-milligram figure is the one to optimize, and the 30 mg wins on it. Our best retatrutide source page sets out the scoring behind that judgement.
Cost per research unit, which is the number people actually feel
Per milligram is the comparison figure. Cost per research unit is the operating figure, and it is the one that decides whether a supply lasts a study phase or runs out halfway through it.
The arithmetic is laboratory arithmetic and it is not complicated. Take the vial strength, divide by the working concentration you intend to reconstitute to, and you have the number of units the vial yields. Divide the discounted vial price by that yield and you have the cost per unit. A 30 mg vial produces three times the units of a 10 mg vial at 2.53 times the price, which is the same 16% advantage expressed in a form you can budget against.
Two practical notes attach to that. Reconstituted peptide has a shorter usable window than the sealed lyophilized powder, so a large vial only stays cheap per unit if the yield is actually consumed. And the whole calculation is downstream of the labeled strength, which is why the certificate matters before the spreadsheet does. Which formats are actually sold, and what a listing has to disclose about strength, is a separate question from what the vial costs.
Bulk tiers, thresholds, and the total that actually appears
Two mechanisms sit on top of the vial price. Bulk tiers take 3% off list at three units, 5% at five, and 10% at ten. Free shipping applies above $250.
Both are worth checking rather than assuming, because thresholds can read the pre-discount subtotal or the post-discount total, and the difference decides whether a single 30 mg order at $125.00 ships free. Put the order together, apply the code, and read the final line before you pay. If a stated saving does not appear in the total, it did not apply, whatever the product page said.
The retatrutide cost and price question this audience keeps leaving out
On a site about lean mass the vial is not the biggest line in the budget, and treating it as such is how people end up smaller rather than leaner.
The Phase 2 results published in the New England Journal of Medicine in 2023 showed a mean weight reduction of about 24% at 48 weeks on the 12 mg arm. Across the incretin trial literature roughly a quarter to a third of total weight lost is fat-free mass. Apply that fraction to a reduction of that size and the absolute quantity of tissue involved stops being a footnote. The mechanism is set out in myostatin inhibitors and GLP-1 muscle loss.
The countermeasures have costs of their own. Protein intake high enough to support a steep deficit is a grocery line, not a supplement line. Maintaining hard resistance training through a period of low energy availability costs time and recovery capacity rather than money, and it is the single input most consistently associated with holding lean tissue. Those are covered in protein intake and myostatin and resistance training and myostatin. Adherence through that stretch is its own line in the budget, and the compounds marketed at it are costed the same way in Selank price.
Measurement costs something too. Scale weight cannot distinguish fat from fat-free mass, so a body-composition method of some kind is what turns the spend into information. The pharmacological answer to the same problem, activin pathway blockers such as bimagrumab, is not for sale at any price, because it is still in trials.
What an unusually low price should prompt you to check
Cost per milligram is arithmetic performed on a stated strength. If the strength is wrong, the arithmetic is wrong, and a listing at $3/mg for unverified material is not cheaper than a verified $4.17/mg, it is a different product.
That matters more here than on a milder compound. Every downstream concentration figure a researcher works with derives from the milligram number on the label. An overstated label produces a solution weaker than intended, an understated one produces a solution stronger than intended, and unplanned aggressive incretin exposure is precisely the scenario that costs lean tissue.
So a price below the market band is a prompt to look at the documentation, not a reason to move faster. What to look for is set out in retatrutide where to buy.
Frequently asked questions
What is the current retatrutide price per milligram?
The 10 mg vial works out at $4.95/mg at $49.50 with code PEPTIDEDECK, and the 30 mg vial at $4.17/mg at $125.00. Those are the discounted figures; at list price the same vials are $9.90/mg and $8.33/mg.
Will insurance ever cover retatrutide?
Not while it is unapproved. Coverage requires a product with marketing authorization and a billing code. If the Phase 3 TRIUMPH program leads to approval, an approved branded product would enter the normal coverage system, but research material sold today would not become reimbursable.
Is buying the 30 mg vial always the cheaper option?
Per milligram, yes: $4.17 against $4.95, and $125.00 against $148.50 for the same 30 mg bought as three smaller vials. The 10 mg is the better first purchase only when the point of the order is to verify a supplier at low outlay.
Do the bulk tiers stack with the discount code?
The tiers are quoted as 3%, 5% and 10% off list at three, five and ten units. Whether they combine with a code is a checkout question rather than a policy you should assume, so build the cart, apply the code, and read the final total before paying.
Why does the cheapest listing on the market not win?
Because price per milligram assumes the milligrams are real. Without a batch-specific certificate from a named third-party laboratory, a low unit price is a number attached to an unknown quantity, and every concentration calculation built on it inherits the error.
This article is for educational purposes only and is not medical advice. Retatrutide is an investigational compound with no marketing authorization in any market, and material sold by research suppliers is labeled for laboratory use only and not for human consumption. Speak with a qualified healthcare professional before making any decision involving peptides, injections, or off-label compounds.